

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |   |
|--|--|---|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C07C 59/245, 59/265, A61K 31/19</b>   | <b>A1</b>  | <b>(11) International Publication Number:</b> <b>WO 96/36585</b><br><b>(43) International Publication Date:</b> 21 November 1996 (21.11.96) |
| <b>(21) International Application Number:</b> PCT/US96/06554<br><b>(22) International Filing Date:</b> 15 May 1996 (15.05.96)<br><br><b>(30) Priority Data:</b><br>08/440,968 15 May 1995 (15.05.95) US<br><br><b>(60) Parent Application or Grant</b><br><b>(63) Related by Continuation</b><br>US 08/440,968 (CIP)<br>Filed on 15 May 1995 (15.05.95)<br><br><b>(71) Applicant (for all designated States except US):</b> SABINSA CORPORATION [US/US]; Unit #6, 121 Ethel Road West, Piscataway, NJ 08854 (US).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> MAJEED, Muhammed [US/US]; Unit #6, 121 Ethel Road West, Piscataway, NJ 08854 (US). BADMAEV, Vladimir [US/US]; Unit #6, 121 Ethel Road West, Piscataway, NJ 08854 (US). RAJENDRAN, R. [IN/TN]; #1382, Southend Main Road, 9th Block, Jayanagar Eastend, Bangalore 69 (IN). | <b>(74) Agents:</b> MURRAY, Robert, B. et al.; Nikaido, Marmelstein, Murray & Oram L.L.P., Metropolitan Square, Suite 330 - G Street Lobby, 655 15th Street N.W., Washington, DC 20005-5701 (US).<br><br><b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i> |   |
| <b>(54) Title:</b> A NEW PROCESS FOR THE PRODUCTION OF POTASSIUM HYDROXY CITRIC ACID, AND COMPOSITIONS CONTAINING THE POTASSIUM HYDROXY CITRIC ACID<br><br><b>(57) Abstract</b><br><br>The present invention provides new processes for the synthesis or isolation of hydroxy citric acid in the form of a potassium salt from Garcinia fruit. The present invention also provides compositions containing the potassium hydroxy citrate for use as appetite suppressants.   |  |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |                          |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia                  | GB | United Kingdom                           | MW | Malawi                   |
| AT | Austria                  | GE | Georgia                                  | MX | Mexico                   |
| AU | Australia                | GN | Guinea                                   | NE | Niger                    |
| BB | Barbados                 | GR | Greece                                   | NL | Netherlands              |
| BE | Belgium                  | HU | Hungary                                  | NO | Norway                   |
| BF | Burkina Faso             | IE | Ireland                                  | NZ | New Zealand              |
| BG | Bulgaria                 | IT | Italy                                    | PL | Poland                   |
| BJ | Benin                    | JP | Japan                                    | PT | Portugal                 |
| BR | Brazil                   | KE | Kenya                                    | RO | Romania                  |
| BY | Belarus                  | KG | Kyrgyzstan                               | RU | Russian Federation       |
| CA | Canada                   | KP | Democratic People's Republic<br>of Korea | SD | Sudan                    |
| CF | Central African Republic | KR | Republic of Korea                        | SE | Sweden                   |
| CG | Congo                    | KZ | Kazakhstan                               | SG | Singapore                |
| CH | Switzerland              | LI | Liechtenstein                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LK | Sri Lanka                                | SK | Slovakia                 |
| CM | Cameroon                 | LR | Liberia                                  | SN | Senegal                  |
| CN | China                    | LT | Lithuania                                | SZ | Swaziland                |
| CS | Czechoslovakia           | LU | Luxembourg                               | TD | Chad                     |
| CZ | Czech Republic           | LV | Latvia                                   | TG | Togo                     |
| DE | Germany                  | MC | Monaco                                   | TJ | Tajikistan               |
| DK | Denmark                  | MD | Republic of Moldova                      | TT | Trinidad and Tobago      |
| EE | Estonia                  | MG | Madagascar                               | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                     | UG | Uganda                   |
| FI | Finland                  | MN | Mongolia                                 | US | United States of America |
| FR | France                   | MR | Mauritania                               | UZ | Uzbekistan               |
| GA | Gabon                    |    |  | VN | Viet Nam                 |

A NEW PROCESS FOR THE PRODUCTION OF POTASSIUM HYDROXY  
CITRIC ACID, AND COMPOSITIONS CONTAINING THE POTASSIUM  
HYDROXY CITRIC ACID

Background of the Invention

5     Field of the Invention

          The invention is directed to new processes for making  
hydroxy citric acid in a form that is stable and  
biologically active. Compositions containing the potassium  
hydroxy citric acid are useful as natural appetite  
10     suppressants.

Description of Related Art

          During the 1970s, scientists at Brandeis University  
and at Hoffman LaRoche demonstrated that synthetic  
hydroxycitric acid, when blended with the diet, had a  
15     marked suppressive effect on weight gain in rats. The  
researchers noted that the HCA-treated rats tended to eat  
less; food consumption was suppressed by 10% or more on  
optimal HCA intakes, that is, when HCA constituted 1% or  
more of the diet.

20     The mechanism by which the HCA affected weight gain  
was not known. Since the brain uptake of HCA appeared to  
be negligible, scientists speculated that the appetite-  
suppressive effect of HCA was exerted not through central  
nervous system (CNS) action, but rather by directly  
25     affecting the metabolic processes of the organism.

          One of the most metabolically active organs in the  
body is the liver. One important function of the liver is  
to insure that the blood maintains adequate concentrations  
of glucose to fuel the body's energy requirements. The

liver can store dietary glucose in the form of the polysaccharide glycogen, and release glucose when blood glucose levels are low. The liver can also synthesize glucose in a complex process known as gluconeogenesis, from either amino acids or lactic acid as starting material. This newly synthesized glucose can either be released into the blood stream to supply energy requirements of body tissues, or can be stored as glycogen for future use.

The direct parasympathetic connection between the liver and the CNS monitors the level of glucose and glycogen in the liver. A high level of glycogen, as a result of high glucose supply, is translated by the CNS as the state of satiety, which results in decreased craving for food.

Since increased glycogen in the liver aids satiety, the effect of HCA on gluconeogenesis in rat liver has been studied. It has been found that the rate of gluconeogenesis, from lactate or the amino acid alanine, was approximately doubled in HCA-treated rats. This result provides support for the idea that HCA causes the observed appetite suppression via altering the rate of gluconeogenesis.

However, it appears unlikely that reduction of food intake can entirely account for the substantial reductions in weight gain seen in HCA-treated rats. For example, in one study, the net reduction in food consumption during the 80 day study period amounted to only 4% - and yet the rats had gained 78% less weight than the controls over

this period. Other studies, providing less dramatic results, suggested that the reduction of weight gain was disproportionately large compared to the reduction in food consumption.

5           Because of this discrepancy between considerable weight loss versus a meager appetite suppression, it has been postulated that HCA exerts a mechanism which increases fat burning, which in turn could decrease body weight, in addition to affecting gluconeogenesis.

10           Fat burning, or oxidation, plays a prominent role in liver metabolism. Liver metabolic activity accounts for over a quarter of the total body oxygen consumption in a subject at rest. The substantial energy needs of the liver are met largely by oxidation of fat. The dietary  
15 fat is absorbed by liver cells, which oxidize or burn it for energy in the mitochondria. The fats are transported from the cell cytoplasm into the liver mitochondria, by linking them to the special transporting molecule L-carnitine. This reaction is facilitated by the enzyme  
20 carnitine acyltransferase.

          Carnitine acyltransferase is inhibited by malonyl CoA, which can be obtained from conversion of acetyl CoA. Malonyl CoA, can not only inhibit the fat burning process, but also increase the body fat synthesis, since it is the  
25 direct precursor for the synthesis of fat and cholesterol. The acetyl CoA is synthesized in mitochondria, but it has to be transported to the cell cytoplasm to exert its biochemical action. However, it cannot be transported to the cytoplasm from mitochondria before it is converted to

citric acid. Thus, citric acid is a transportable form of acetyl CoA. Citric acid, once in the cytoplasm, is converted to acetyl CoA with the help of the enzyme - citrate lyase. HCA was found to be an extremely potent competitive inhibitor of citrate lyase ( $K_i = .15 \mu M$ ). The affinity of the enzyme for HCA was over a hundred times greater than the affinity of the enzyme for citric acid. This action was afforded only by a HCA in a pure acid form, but not in the lactone form.

The significance of citrate lyase inhibition by HCA is that without active citrate lyase, little acetyl CoA could reach the cytoplasm. This in turn would limit the availability of malonyl CoA and slow the synthesis of fats and cholesterol, while disinhibiting the metabolic breakdown of fat, or oxidation of fat.

In light of the considerations noted above, it is likely that the ability of HCA to promote fat loss in humans results primarily from the stimulation of fat oxidation.

Activation of fat oxidation in the liver also tends to stimulate gluconeogenesis, primarily due to increased activity of the key enzyme pyruvate carboxylase. This in turn may replenish the stores of liver glycogen, and send a message of satiety to the brain center.

The drawbacks of HCA use as a weight loss compound stem from the following problems:

1. The poor technology of HA extraction from the fruit of *Garcinia cambogia* often provides HCA in lactone

form, which is inactive, or less active, in inhibiting the citrate lyase;

2. The HCA, if not stabilized chemically, has natural propensity to be converted to the lactone form in aqueous solutions and in the gastrointestinal tract, i.e., without absorption of HCA in pure acid form, the HCA can not inhibit the citrate lyase; and

3. High concentrations of HCA, that is, 1% or more (by weight) of the daily dietary intake, are required to exert the metabolic activity, because of poor cellular uptake. Without absorption of HCA, and the presence of HCA in the cytoplasm in pure acid form, HCA can not inhibit citrate lyase and exert its inhibitory activity on acetyl CoA formation.

In the past, it has been difficult to isolate hydroxy citrate in a form which is both stable and biologically active. Hydroxy citric acid exists in two forms, the free acid form and the lactone form. The free acid form is biologically active and the lactone form is inactive. However, the free acid form is not stable and gets converted to its lactone form, which is stable but inactive.

One prior art isolation procedure, that of Y.S. Lewis et al., in Phytochem 1965, Vol. 4, pp. 610-625, results in the isolation of hydroxy citric acid lactone.

I. WATER EXTRACT OF (-) HYDROXYCITRIC ACID FROM FRUIT OF GARCINIA CAMBOGIA (Lewis, Y.S. and

Neelakantan, S., phytochemistry (1965) Vol. 4; pp. 619-625)

The prior art procedure to obtain (-)HCA from *Garcinia cambogia* on a large scale included the following procedure:

1. The dried rind was cooked with about three volumes of water in an autoclave (101b/in<sup>2</sup>) for 15 minutes;
2. The resulting extract was filtered through a cloth and then through a paper filter;
3. The obtained filtrate was concentrated to a small volume, and the alcohol precipitation method removed pectin contamination;
4. The clear filtrate was then treated with potassium hydroxide (alkali) to form viscous, dark, heavy liquid; this treatment resulted in formation of a hygroscopic material consisting of potassium salt of hydroxycitric acid;
5. The clear supernatant was decanted off and the oily liquid washed with 60% alcohol several times;
6. By repeated treatment with absolute alcohol, the material could be dried to a pale yellow hygroscopic powder, which formed pure alkali salt;
7. Aqueous solutions of the alkali salt were passed through a cation-exchange resin (Zeocarb 215) for recovery of the acid;
8. The obtained (-)HCA was chemically unstable, and upon evaporation formed lactone.

Another process for isolation of lactone was reported by Y.S. Lewis.

II. ACETONE EXTRACT OF (-) HYDROXYCITRIC ACID FROM  
THE FRUIT OF GARCINIA CAMBOGIA (Lewis, Y.S.  
(1981) Methods in Enzymology, Vol. 77;  
Published by Academic Press; pp. 613-619).

5

1. One kg of fruit of Garcinia cambogia is kept in  
1500 ml of acetone in an overnight;

2. The fruit is re-extracted in a similar manner;

10

3. Acetone is removed from the combined extracts by  
distillation;

4. The viscous residue is stirred with 1 liter of  
water at 45-50°C;

5. The mixture is filtered through cheesecloth;

15

6. The precipitated insoluble material is removed  
by filtration;

7. The reddish brown filtrate is treated with  
activated charcoal at 80-90°C and concentrated to a thick  
syrup;

20

8. The syrup is "seeded" with a few crystals of the  
lactone and left overnight;

9. The yield is vigorously extracted with 3 liters  
of ether;

25

10. The combined extracts are dried over anhydrous  
sodium sulfate;

11. Ether is then removed, and the remaining  
material is white solid, consisting mainly of lactone.  
The yield is approximately 150 gm.

### Summary of the Invention

The principle of the present invention is to provide technology for extraction or synthesis of HCA in pure acid form, and technology for chemical modification of HCA to afford chemically stable product, which will not convert into lactone form, which will not be hygroscopic, and which is soluble in aqueous solutions and easily absorbable by the gastrointestinal tract.

The invention provides HCA by combining it with potassium into potassium hydroxycitrate - a water soluble salt. Potassium is an ion primarily found in the cell cytoplasm, and it can easily cross from outside the cell to inside the cell. The cell membrane permeability for potassium is 100 times higher than for sodium and 25 times higher than for chloride. Potassium salt of HCA acts as a transporter of HCA inside the cell, where the biochemical action of HCA is exerted.

### Brief Description of the Drawings

Figure 1 is an infrared spectrum of potassium hydroxycitrate.

Figure 2 is a thermogram of potassium hydroxycitrate.

Figure 3 is a NMR spectrum of potassium hydroxycitrate.

Figure 4 is an HPLC chromatogram of Potassium Hydroxycitrate.

Figure 5 shows the results of a stability test on liquid CITRIN®.

Description of the Preferred Embodiments

The processes of the present invention are used to isolate hydroxy citric acid as potassium hydroxy citrate from a natural source of Garcinia species. Preferred  
5 sources include Garcinia cambogia and Garcinia indica.

Alternatively, the potassium hydroxy citrate may be formed chemically by a synthetic route in which the product has the same good characteristics as the potassium hydroxy citrate isolated from Garcinia by the process of  
10 the invention.

This is a novel approach to obtain hydroxy citrate in a synthetic and/or biotechnology process utilizing as a substrate, citric acid, from both natural and artificial sources. Closely related to hydroxy citric acid the  
15 citric acid is a tribasic acid abundant in fruit juices, e.g., lemon, orange, apples. Citric acid may be commercially obtained from fruits or, alternatively, by fermentation by growing a strain of Penicillium on a medium rich in carbohydrate. Citric acid is also present  
20 in various fruits of Garcinia species and in Tamarind fruit. Tamarind pulp contains free organic acids, about 10% of citric, tartaric and malic acids, and their salts, about 8% of the potassium salts.

The present invention provides technology for  
25 converting citric acid from any source into the pure acid form, the lactone free hydroxy citric acid. The invention provides hydroxy citric acid which is ready-to-use end product, e.g., liquid or solid form of the hydroxy citric

acid, or which is subsequently combined with an alkali metals, e.g., potassium, transition metals, e.g., magnesium, calcium, or entered into any other chemical combination to obtain a chemically stable and biologically effective organic or inorganic complex of the hydroxy citric acid for human and animal consumption - to afford body weight reduction with continuous use.

The following procedures provide chemically stable alkali salts of the hydroxy citric acid, which are not hygroscopic, and which are soluble in aqueous solutions and is easily absorbable by the gastrointestinal tract.

#### SYNTHETIC PROCESS TO OBTAIN HYDROXY CITRIC ACID

The following procedure is used to obtain the pure form of hydroxy citric acid from any source of citric acid:

- (1) CITRIC ACID\* -- Dehydration ( $-H_2O$ )-ACONITIC ACID
- (2) ACONITIC ACID\* -- Peracetic acid in acetic acid - EPOXIDE OF ACONITIC ACID
- (3) EPOXIDE OF ACONITIC ACID -- lipase (obtained commercially or by action of microorganisms, e.g., yeast (Saccharomyces) or bacteria (Pseudomonas) - PURE FORM OF HYDROXY CITRIC ACID (CITRIN®).

\* Since citric acid and aconitic acid form part of the Krebs cycle and the glyoxalate cycle in microorganisms, the novel process to obtain the hydroxy citric acid in a synthetic form also includes a biotechnology method to obtain the acid as a result of genetic engineering method

(e.g., mutation of genetic material of pseudomonas sp. with ultraviolet rays or chemical mutagens like nitroso-guanidine to obtain ready-to-use pure form of the hydroxy citric acid).

## 5 ISOLATION PROCESS TO OBTAIN FOR HYDROXY CITRIC ACID

For the process of isolation from Garcinia, the fruit of the Garcinia species is extracted with an alkyl alcohol. Preferred alcohols include methyl alcohol, ethyl alcohol, propyl alcohol, and isopropyl alcohol. Especially  
10 preferred is methanol. The extract is treated with a suitable alkali to precipitate the potassium hydroxy citrate. Preferred alkalis include potassium hydroxide, potassium carbonate, etc. Most preferred alkali is potassium hydroxide.

15 The general process includes the following steps. Garcinia fruit is extracted with an alkyl alcohol and the extract is collected. The extraction step may be performed more than once. The extract is then treated with an alcoholic solution containing alkali. (If the extraction  
20 step is repeated, the extracts are combined and treated with an alcoholic solution containing alkali.) The resultant mass is heated to above ambient temperature and pH is adjusted to make the solution alkaline. The pH of the solution is normally between 8 to 11.5. The product is  
25 filtered and washed with alcohol. The product is then dried.

A preferred process of the invention is as follows. Garcinia fruit is extracted with an alkyl alcohol at above ambient temperature. This is done at or above atmospheric pressure. The extract is collected. The extraction step is repeated at least three times. The extracts are combined and treated with an alcoholic solution containing alkali. The resultant mass is heated to above ambient temperature and pH is adjusted to make the solution alkaline. The pH of the solution is normally between 8 to 11.5. The product is filtered and washed with alcohol. The product is dried at or above 25°C under vacuum or at atmospheric pressure or under inert atmosphere, like nitrogen. The dried product is milled, sifted, blended and packed under nitrogen blanket to obtain product. The yield from 500 kgs of garcinia fruit ranges from 60 to 150 kgs of potassium hydroxy citrate based on the hydroxy citric acid content present in the fruit.

#### STABILIZERS OF PURE FORM OF HYDROXY CITRIC ACID

The free hydroxy citric acid has a natural propensity to covert into a more stable form of the lactone, which is however biologically ineffective for the purpose of weight loss treatment. In the present process, the free acid form can be stabilized as potassium salt to retain the activity.

Another novel way to stabilize the hydroxy citric acid is without chemical alteration by maintaining it in a liquid form at low pH, which is sufficient to prevent lactone formation. Enclosed graphs illustrate an

accelerated stability test of natural hydroxy citric acid in water CITRIN® liquid), which shows that the product does not develop an excessive amount of lactone over time.

Yet another novel way to stabilize the pure hydroxy  
5 citric acid is to use naturally occurring substances which prevent conversion of the acid form into the lactone form. These substances can be exemplified by a group of proteins discovered in the University of Osaka, Japan, and are called chaperon proteins. Chaperon proteins have ben  
10 originally isolated from microorganism Pyococcus, and were shown to protect the chemical structure of proteins like lactic dehydrogenase enzyme against denaturing influences of the environment, e.g., high temperature. The chaperon or chaperon-like compounds can be used to stabilize the  
15 pure acid against conversion into the lactone form.

#### UNIQUE ASPECTS OF THE PROCESSES OF THE PRESENT INVENTION

Hydroxy citric acid exists in two forms, i.e., free acid form and lactone form. The free acid form is biologically active and the lactone form is inactive.  
20 However, the free acid form is not stable and this gets converted to its lactone form, which is stable but inactive. In the processes of the present invention, the free acid form is isolated and stabilized as potassium salt to retain the activity. This is one of the  
25 advantages of the present invention.

Another unique aspect of the processes is that the potassium hydroxy citrate produced is water soluble and

therefore readily available in the biological system for its bioefficacy.

#### EXAMPLE

5 The detailed procedure used to obtain the product trademarked at CITRIN®-K is as follows:

1. The 500 kg of Garcinia fruit is extracted with 1500 l of methanol at about reflux temperature for 3 hours;
2. This is filtered through the cloth filter to  
10 collect the first extract;
3. Additional 1500 l of methanol is added to the Garcinia fruit and refluxed for about 3 hours;
4. This is filtered to collect the second extract;
5. The 1500 l of methanol is added again to the  
15 Garcinia fruit and refluxed for 3 hours;
6. This is filtered, and the third extract is collected;
7. All the three extracts are combined;
8. The combined extracts are treated with  
20 methanolic potassium hydroxide at pH 10;
9. This is again refluxed for about 3 hours to attain constant pH 10 to precipitate potassium hydroxycitrate;
10. The precipitate is filtered and washed with 500  
25 l of methanol;
11. The precipitate is dried under vacuum at about 70°C;

12. The dried product is milled, sifted, blended and packed under nitrogen blanket to obtain product trademarked at CITRIN®-K;

13. The methanolic mother solution is distilled to recover methanol;

14. The yield from 500 kg of Garcinia fruit is about 150 kg of potassium hydroxycitrate.

The specifications of the product CITRIN®-K is given below:

10        SPECIFICATIONS

Molecular Structure

|    |                            |   |
|----|----------------------------|---|
|    | Molecular Formula          | $C_6H_5K_3O_8 \cdot H_2O$   |
|    | Molecular weight           | 340.41  |
| 15 | Description                | Beige to pale brown colored powder  |
|    | Solubility                 | Soluble in water, acids and aqueous alcohols. Insoluble in solvents like methanol, alcohol, chloroform, benzene, etc. |
| 20 | Loss on Drying             | Not less than 3% and not more than 6.0%   |
|    | pH of 5% solution in water | 7.0 to 9.0  |
|    | Specific Rotation          | -18° to -25° on anhydrous basis   |

16

Potassium content not less than 30 % by weight on anhydrous basis

Hydroxy citric Not less than 50% on anhydrous basis

5 acid content

Lactone content (HPLC) less than 2% by weight

#### IDENTIFICATION

##### a) By IR Spectrum

10 The infrared absorption spectrum of a potassium bromide dispersion of potassium hydroxy citrate, previously dried, exhibits maxima only at the same wavelength as that of similar preparation of Working Standard. IR Spectrum of Potassium Hydroxy Citrate Working Standard is shown in FIGURE 1.

##### 15 b) For Potassium

Produces yellow or orange-yellow precipitate with sodium cobaltinitrite solution.

20 Dissolve 50 mg of 1 ml of water, add 1 ml of dilute acetic acid and 1 ml of freshly prepared 10% w/v solution of sodium cobaltinitrite. A yellow or orange-yellow precipitate forms immediately.

##### c) For Citrate

25 Dissolve 0.5 g in a mixture of 10 mL of water and 2.5 mL of 2 N nitric acid. Add 1 mL of mercuric sulphate solution heat to boiling, and add 1 mL of potassium permanganate solution: a white precipitate is

formed.

d) By Paper Chromatography

Mobile Phase

Butanol (4): Acetic Acid (1): Water (5)

5 Prepare 100 mL of mobile phase in separator and mix well. Allow it to separate and use the upper layer as mobile phase.

Stationary Phase:

Whatman filter Paper No. 1

10 Sample Preparation

Dissolve 100 mg of the sample in 1 mL of water and dilute to 10 mL with methanol in a volumetric flask.

Standard Preparation

15 Dissolve 100 mg of the Working Standard in 1 mL of water and dilute to 10 mL with methanol in a volumetric flask.

Procedure

20 Apply separately equal volume (10  $\mu$ l) of sample and standard preparation and develop the chromatogram in the chamber previously saturated with mobile phase. After developing the chromatogram to 3/4, the paper is removed and dried in a current of air.

Detection

25 The paper is sprayed with sodium metavanadate solution (5% w/v) and observed for the orange spot. The Rf value of the spot obtained from the sample solution is same as that of the Standard solution.

**LOSS ON DRYING**

Limit: Not less than 3.0% and not more than 6.0%

The material shows weight loss of about 5% when dried at 150°C under vacuum for four hours. This weight  
5 loss is due to the release of water of hydration from the molecule.

**THERMAL ANALYSIS**

Potassium hydroxy citrate is analyzed by Thermogravimetry. This technique is used to estimate the  
10 presence of water of hydration in the product. The details of the methods are given below:

In this method, the sample is heated under nitrogen/argon atmosphere and the weight loss is recorded continuously.

15 Limit: The weight loss is not more than 6.0%

Analysis is carried out using about 3 mg of the sample accurately weighed. The temperature setting is from 30°C to 400°C with the rate of heating as 10°C per minute. The heating of the sample is done under  
20 nitrogen/argon atmosphere flowing at a flow rate of 40 mL/min.

From the TGA thermogram, it is observed that there is weight loss between 180°C and 250°C to a level of about 5% which indicates the presence of water of  
25 hydration.

The percentage loss corresponds to one molecule of water.

A typical thermogram is given in FIGURE 2.

#### pH OF SOLUTION

pH of 5.0% w/v solution is between 7.0 and 9.0.

Dissolve 2.5 g in 50 ml of water and determine  
5 the pH using suitable calibrated pH meter.

#### SPECIFIC ROTATION

Between  $-18.0^{\circ}$  and  $-25.0^{\circ}$  calculated on anhydrous basis.

Weigh accurately about 1 g of the sample and  
10 transfer into a 100 ml volumetric flask, dissolve in water, dilute to volume and mix.

Measure the rotation using suitable polarimeter at about  $25^{\circ}\text{C}$ .

#### ASSAY

15 Assay of the product is estimated by estimating the content of HYDROXY CITRIC ACID and POTASSIUM.

For determination of HYDROXY CITRIC ACID, the following methods are employed:

- i) TITRATION METHOD
- 20 ii) HPLC METHOD

The details of the methods are given below:

Limit: Content of HCA is not less than 50.0% calculated on anhydrous basis

**TITRATION METHOD**

Weigh accurately about 200 mg of the sample and transfer into a beaker. Add 100 ml of water and dissolve. Pass the solution through cation ion exchange resin column and collect the affluent into a 1 L flask. Rinse the beaker with water and pass the washings through the column. Wash the column with distilled water until the elute shows a pH of 4.0 to 4.5. Adjust the volume to about 500 ml and titrate with 0.1 N sodium hydroxide solution using phenolphthalein solution as indicator.

Perform a blank titration after eluting 500 ml of water through the column.

Calculation:

$$\frac{(\text{Titre value} - \text{blank value}) \times 0.1 \text{ N of NaOH} \times 0.006933 \times 100 \times 100}{0.1 \times \text{Weight of the sample} \times (100 - \text{LOD})}$$

Note 1 Column Preparation and Regeneration:


About 75 g of cation exchange is packed in a column of 2 cm diameter. Soak the column for 30 minutes in 2 N HCl. Wash thoroughly with distilled water to get a pH of 4.0 to 4.5

After the analysis, the cation exchange resin is soaked with 2 N HCl for 3 hours. It is then washed well with distilled water until the pH of the washings shows 4.0 to 4.5

Note 2 The above method is based on the published research paper titled "Chemical Constituents of Kokum Fruit Rind" by CFTRI, Mysore.

Note 3 Specification of the cation exchange resin is given in **FIGURE 3**

Note 4 The factor of 0.006933 is arrived at by the following calculation



[2 moles of HCA].

416 g of HCA = 6000 ml of 1 N NaOH

or

6000 ml of 1 N NaOH = 416 g of HCA

10 1 ml of 1 N NaOH =  $\frac{416}{6000} = 0.06933$  g

1 ml of 0.1 N NaOH =  $\frac{0.06933}{10} = 0.006933$  g

#### HPLC METHOD

15 In this method, normally, (-) Threo Hydroxy Citric Acid Ethylene Diamine Salt (Fluka Standard) is used as a Standard to estimate Hydroxy Citric Acid content in Potassium Hydroxy Citrate. This Standard is not readily available, and therefore an alternate standard, Potassium

20 Hydroxy Citrate is preferred. A pure sample of Potassium Hydroxy Citrate has been synthesized and validated against the Fluka Standard (Figure 4). In the method given below, Potassium Hydroxy Citrate is used as a Working Standard (WS).

Mobile Phase

Prepare 0.01 N sulfuric acid, filter and degas.

Sample Preparation

5 50 mg of the sample is accurately weighed,  
dissolved in water and diluted to 25 ml with water.

Standard Preparation

50 mg of Potassium Salt of Hydroxy Citric Acid  
(WS) is dissolved in 10 ml of water, and diluted to 25 ml  
with water.

10

Chromatographic system

The liquid chromatograph is equipped with 210 nm  
detector and a 4.6 x 250 mm organic acid column (Vydac  
make). The flow rate is about 1 ml per minute.  
Chromatograph the standard preparation and calculate the  
15 Relative Standard Deviation (RSD) for replicate  
injections. The RSD is not more than 2.0%.

Procedure

Separately inject equal volume (20  $\mu$ l) of sample and standard preparation and record the responses obtained for the major peaks.

5           Calculation:

Area of the sample X standard weight X (100-water content of STD

$$\frac{\text{X HCA content of standard}}{\text{Area of the standard X sample weight (100 - LOD of Sample)}}$$

10       =     Hydroxy Citric Acid content in the sample

**ESTIMATION OF POTASSIUM**

This estimation is done by two methods:

- i)     FLAME PHOTOMETRY
- ii)    ATOMIC ABSORPTION

15           The details of the methods are given below:

Limit of Potassium:

Not less than 30.0% calculated on anhydrous basis

**FLAME PHOTOMETRY**Standard Stock Solution

Weigh accurately about 1.84 g of Potassium Chloride, previously dried at 105°C for 2 hours and  
5 transfer into a 250 ml volumetric flask, add water to volume and mix.

Lithium Diluent Solution

Transfer 1.04 g of Lithium Nitrate to a 1000 ml volumetric flask, add a suitable nonionic surfactant, add  
10 water to volume and mix

Standard Preparation

Pipette 5 ml of stock solution into a 50 ml of volumetric flask, dilute to volume with water and mix. Transfer 5 ml of this solution to a 100 ml volumetric  
15 flask and dilute with lithium diluent solution to volume and mix.

Assay Preparation

Weigh accurately about 3 g of the sample and transfer into a 250 ml volumetric flask, add water to

dissolve and dilute to volume and mix. Pipette 5 ml of this solution into a 50 ml volumetric flask, add water to volume and mix. Transfer 5 ml of this to a 100 ml volumetric flask, dilute with lithium diluent solution to  
5 volume and mix.

#### Procedure

Using a suitable flame photometer adjust to read zero with lithium diluent solution concomitantly determine the emission readings for Standard and Sample preparations  
10 at about 766 nm

Calculate the content of Potassium as follows:

Emission reading of Standard X Weight of Standard X 39.1  
Emission reading of Sample X Weight of Sample X 74.55

#### ATOMIC ABSORPTION

##### 15 Potassium Stock Solution

Dissolve 190.7 mg of potassium chloride, previously dried at 105°C for 2 hours, in water. Transfer to a 500 ml volumetric flask, dilute with water to volume and mix. transfer 5 ml of this solution to a 100 ml  
20 volumetric flask, dilute to volume with water and mix.

Standard Preparation

To separate 100 ml volumetric flask, transfer 10, 15 and 20 ml respectively of Potassium stock solution. To each flask, add 2 ml of sodium chloride solution (1 in 5) and 1 ml of hydrochloric acid, dilute with water to volume and mix.

Assay Preparation

Weigh accurately about 1 g of the sample and transfer into a 500 ml volumetric flask dissolve in water, dilute to volume and mix. Transfer 5 ml of this to a 100 ml volumetric flask, dilute to volume with water and mix. Transfer again 5 ml of this solution to a 100 ml volumetric flask, add 2 ml of sodium chloride solution (1 in 4) and 1 ml of hydrochloric acid, Dilute with water to volume and mix.

Procedure

Concomitantly determine the absorbencies of the Standard preparations and assay preparation at the potassium emission line of 766.5 nm, with a suitable atomic absorption spectrophotometer equipped with a

potassium hollow cathode lamp and an air acetylene flame, using water as the blank. Plot the absorbance of standard preparation versus concentration in  $\mu\text{g}$  per ml of potassium and draw the straight line best fitting the three plotted points. From the graph so obtained, determine the concentration, in  $\mu\text{g}$  per ml of potassium in the assay preparation.

Calculate the content of potassium in mg as follows:

200 x C where 'C' is concentration in  $\mu\text{g}$  per ml

Calculate the percentage of potassium as follows:

$$\frac{200 \times 'C' \times 100}{\text{Wt. taken in mg}}$$

#### 15 MICROBIAL ASSAY

Total Plate Count, *E. coli*, *Salmonella*, yeasts and molds are estimated as per procedures described in "OFFICIAL METHODS OF ANALYSIS - ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTS" (14th Edition, 1990)

The limits are given below:

|   |                   |             |
|---|-------------------|-------------|
|   | Total Plate Count | 10000 cfu/g |
|   | <i>E. coli</i>    | Absent      |
|   | Salmonella        | Absent      |
| 5 | Yeasts/Molds      | 1000 cfu/g  |

Aflatoxins are estimated by the following procedure, which is based on the methods described in "OFFICIAL METHODS OF ANALYSIS - ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTS" (15th Edition 1990)

10                   Limit: Aflatoxins - Not more than 20 parts per billion

Procedure for estimated Aflatoxins

Apparatus

High speed stirrer (1400 - 1600 rpm with  
15   stainless steel shaft and propeller blade)

Ultra Violet Light

Long wave UV with intensity of 430  $\mu$  watt/cm<sup>2</sup> at  
15 cm at 365 nm

Minicolumn

Borosilicate std wall tubing, Ca 6 (id) x 200 mm  
tapered at one end to ca 2 mm

Densitometer

With fluorometry attachment

5

Reagents

Distilled water or deionized water may be used.

a) Solvents

CHCl<sub>3</sub> and acetone AR grade must be used

b) Potassium hydroxide wash solution

10

0.02 N KOH with 1% KCl. Dissolve 1.12 g  
KOH pellets and 10 g KCl in 1 L H<sub>2</sub>O

c) Sodium hydroxide solution

0.02 N 8.00 g of NaOH/LH<sub>2</sub>O

d) Sulfuric acid solution - 0.03%

15

Dilute 0.3 ml H<sub>2</sub>SO<sub>4</sub> to 1 L

e) Precipitating reagents

i) Copper carbonate, basic

ii) Ferric chloride slurry: Mix 20 g  
anhydrous FeCl<sub>3</sub> with 300 ml H<sub>2</sub>SO<sub>4</sub>

20

f) Diatomaceous earth

Hyflo Super-Cel or equivalent

g) Column Packing

Silica Gel G 60 - 100 mesh; Florisil 100 -  
200 mesh; Alumina neutral 80 - 200 mesh;  
CaSO<sub>4</sub> anhydrous 20 - 40 mesh

5

h) Aflatoxin Standard solutions

Standards from Sigma Chemicals, USA, are  
used.

Preparation of mini column

Tamp small plug of glass wool into tapered end  
10 of column. To column, add to height indicated in  
following order: 30 mm silica gel; 10 mm neutral alumina  
and 10 mm CaSO<sub>4</sub>. Tamp small plug of glass wool on top of  
column. Tamp column after each addition to settles  
packing and maintain interfaces as level as possible.  
15 After packing, apply pressure to top glass wool plug with  
5 mm diam. rod. Activate packed columns at 110°C for 1-2  
hours and store in vapor tight container.

Extraction of Aflatoxins

Weigh 50 g sample into stirrer, add 250 ml  
20 CHCl<sub>3</sub>-H<sub>2</sub>O(85+15) and stir it for 30 minutes. Filter  
through Whatman No. 4 filter paper. Collect 150 ml  
filtrate and transfer to 500 ml beaker.

### Purification

To 50 ml beaker, add 170 ml 0.2 N NaOH and 30 ml FeCl<sub>3</sub> slurry and mix well. Add 3 g basic CuCO<sub>3</sub> to sample extract in 500 ml beaker and mix well, add both 1 and 2  
5 mixtures and mix well. Filter the mixture through Whatman No. 4 filter paper in a Buchner funnel using Hyflo supercel bed.

Transfer 150 ml filtrate to 500 ml separator, add 150 ml 0.03% H<sub>2</sub>SO<sub>4</sub> and 10 ml CHCl<sub>3</sub>. Shake vigorously  
10 for 5 minutes and allow to stand for 30 minutes. Transfer lower CHCl<sub>3</sub> layer (13-14 ml) to 125 ml separator. Add 100 ml KOH wash solution, swirl gently for 30 seconds and allow to stand. (If emulsion occurs, drain emulsion into 10 ml test tube add 1 g anhydrous Na<sub>2</sub>SO<sub>4</sub>, stopper, shake  
15 30 seconds and allow to stand (CHCl<sub>3</sub> phase need not be completely clear). If emulsion is not broken, transfer emulsion to 125 separator and wash with 50 ml 0.03% H<sub>2</sub>SO<sub>4</sub>. Collect 3 ml CHCl<sub>3</sub> layer in 10 ml test tube.

### Column Chromatography

20 Transfer 2 ml CHCl<sub>3</sub> solution (extract) to minicolumn, using 5 ml syringe. Hold the column vertically and apply slight air pressure (with the help of

a rubber bulb) to force solvent through column at rate  $\leq$  10 cm/min until solvent appears at tip. Remove rubber bulb and add about 5 ml of elution solvent containing  $\text{CHCl}_3$ -acetone (9:1). Collect the fractions.

- 5                   Examine column under UV lamp for blue fluorescent band at top of Florisil layer (Ca 2.5 cm from bottom of column) indicative of aflatoxin. Collect the fractions corresponding the blue band separately and concentrate to a residue.

10                   TLC

- Dissolve the residue in minimum quantity of  $\text{CHCl}_3$ , and carry out the TLC testing along with authentic sample of Aflatoxins. Solvent system - Benzene: Methanol: Acetic Acid (95:5:5). Quantify the aflatoxin by using TLC
- 15                   densitometer.

STABILITY

- The stability of the product was evaluated in solid state and in aqueous solution in temperature and humidity conditions as specified below. The following parameters
- 20                   of the product were considered: physical appearance,

specific rotation, HCA content by HPLC, lactone content by HPLC.

1. In solid state:

- a) Room temperature,
- 5 b)  $37^{\circ} \pm 2^{\circ}\text{C}$  and  $75\% \pm 2$  relative humidity
- c)  $45^{\circ} \pm 2^{\circ}\text{C}$  and  $75\% \pm 2$  relative humidity

2. In solution form (5% in water)

- a) Room temperature
- b)  $37^{\circ} \pm 2^{\circ}\text{C}$
- 10 c)  $45^{\circ} \pm 2^{\circ}\text{C}$

Conclusion

The product is found to be stable under stress conditions (higher temperature and higher humidity) for a minimum of 90 days. These results indicate that the  
15 product will be stable for about 5 years under normal storage conditions.

CLAIMS

We claim:

1. A process for the production of potassium hydroxy  
citric acid comprising:

- a) providing Garcinia fruit;
- b) extracting the Garcinia fruit with an alkyl  
5 alcohol;
- c) treating the extract with potassium hydroxide and  
precipitating the potassium hydroxy citrate; and
- d) recovering the potassium hydroxy citrate.

2. The process of claim 1 wherein recovering the  
potassium hydroxycitrate comprises the steps:

- a) filtering the precipitate;
- b) washing with an alkyl alcohol; and
- 5 c) drying.

3. A process for the production of potassium hydroxy  
citric acid comprising:

- a) providing Garcinia fruit;

- b) extracting the Garcinia fruit with methanol at  
5 reflux temperature and collecting the extract;  
c) repeating step b) an additional two times;  
d) combining the three extracts of steps b) and c);  
e) treating the combined extracts with methanolic  
potassium hydroxide at about pH 10 and reflux for about  
10 three hours to precipitate potassium hydroxy citrate;  
f) filter the precipitate;  
g) wash with methanol and dry under vacuum; and  
h) mill, sift, blend, and pack the dried product  
under nitrogen.

4. The potassium salt of hydroxy citric acid.

5. A composition suitable for use as an appetite suppressant comprising the compound of claim 4 and a pharmaceutically acceptable excipient.

6. A new technological process for commercial manufacturing of hydroxycitric acid from natural sources, e.g., Garcinia cambogia fruit, obtained in a free acid form as opposed to a lactone form.

7. A new technological process wherein hydroxycitric acid extracted according to claim 1 is used for commercial manufacturing of potassium hydroxycitrate salt.

8. The compound made by the process of claim 1 which contains not less than 50% of hydroxycitric acid in free acid form.

9. The compound made by the process of claim 1 which contains 33 to 38% of elemental potassium.

10. The composition made by the process of claim 1 which is soluble in water.

11. The compound made by the process of claim 1 which is not hygroscopic.

12. The compound made by the process of claim 1 which has specific rotation  $(-)\text{20}^{\circ}$  to  $(-)\text{23}^{\circ}$  on anhydrous basis.

13. The compound made by the process of claim 1 which does not convert to lactone form.

14. The compound made by the process of claim 1 which is stable for 5 years under normal storage conditions.

15. The compound made by the process of claim 1 which is more bioavailable to inhibit cytoplasmic enzyme citrate lyase.

16. The compound made by the process of claim 1 which provides potassium to enter in chemical reaction with chromium and vanadium to enhance biological effect of hydroxycitric acid in oxidizing or burning fats - the  
5 effect that results in a weight loss.

17. A process for the synthesis of hydroxy citric acid comprising:

- a) providing citric acid;
- b) dehydrating citric acid to produce aconitic acid;

- 5           c) treating the aconitic acid obtained in step b)  
with peracetic acid in acetic acid to produce the epoxide  
of aconitic acid;
- d) treating the epoxide of aconitic acid obtained in  
step c) with lipase to produce hydroxy citric acid; and
- 10          e) recovering the hydroxy citric acid.

18. A process for the synthesis of potassium hydroxy  
citric acid comprising:

- a) treating hydroxy citric acid with potassium  
hydroxide to precipitate the potassium hydroxy citrate;
- 5          and
- b) recovering the potassium hydroxy citrate.

1/5




Fig.1

2 / 5




Fig. 2

3/5




Fig. 3

4/5

C-RTA CHROMATOPAC CH=2




Fig. 4




Fig. 5

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/06554

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07C 59/245, 59/265; A61K 31/19

US CL : 562/582, 584; 514/574

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 562/582, 584; 514/574

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS

search terms: hydroxycitrate, hydroxycitric acid, hydroxy citrate, hydroxy citric acid, Garcinia,

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| X         | US, A, 3,764,692 (LOWENSTEIN) 09 OCTOBER 1973, see entire patent.                  | 1-16                  |

RECEIVED  
MAY 15 2001  
OFFICE OF PETITIONS

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

|   |  |
|---|--|
| * Special categories of cited documents:  | *T* Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| *A* document defining the general state of the art which is not considered to be of particular relevance  | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| *E* earlier document published on or after the international filing date  | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *Z* document member of the same patent family  |
| *O* document referring to an oral disclosure, use, exhibition or other means  |  |
| *P* document published prior to the international filing date but later than the priority date claimed  |  |

Date of the actual completion of the international search

25 JULY 1996

Date of mailing of the international search report

23 AUG 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

WILLIAM J. HARRIS

Telephone No. (703) 308-1235